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A Clinical Index for Disease Activity in Cats with Chronic Enteropathy
Abstract
Background: There is a need for a clinically useful, quantitative index for measurement of disease activity in
cats with chronic enteropathy (CE).
Objective: To develop a numerical activity index that is of practical value to clinicians treating CE in cats.
Animals: Eighty-two cats with CE.
Methods: Retrospective case review of 59 cats diagnosed with inflammatory bowel disease (IBD).
Prospective validation study of 23 cats having either IBD or food-responsive enteropathy (FRE). Multivariate
regression analysis was used to identify which combination of clinical and laboratory variables were best
associated with intestinal inflammation of IBD. This combination of variables was expressed in a score that
was used as an activity index for the prospective assessment of disease activity and of the effect of treatment in
cats with IBD or FRE.
Results: The combination of gastrointestinal signs, endoscopic abnormalities, serum total protein, serum
alanine transaminase/alkaline phosphatase activity, and serum phosphorous concentration had the best
correlation with histopathologic inflammation and comprise the feline chronic enteropathy activity index
(FCEAI). Positive treatment responses in cats with CE were accompanied by significant (P < .05) reductions
in FCEAI scores after treatment.
Conclusions and Clinical Importance: The FCEAI is a simple numerical measure of inflammatory activity
in cats with CE. The scoring index can be reliably used in the initial assessment of disease severity for both
IBD and FRE and as a measure of clinical response to treatment for these disorders.
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Background: There is a need for a clinically useful, quantitative index for measurement of disease activity in cats with
chronic enteropathy (CE).
Objective: To develop a numerical activity index that is of practical value to clinicians treating CE in cats.
Animals: Eighty-two cats with CE.
Methods: Retrospective case review of 59 cats diagnosed with inﬂammatory bowel disease (IBD). Prospective validation
study of 23 cats having either IBD or food-responsive enteropathy (FRE). Multivariate regression analysis was used to identify
which combination of clinical and laboratory variables were best associated with intestinal inﬂammation of IBD. This com-
bination of variables was expressed in a score that was used as an activity index for the prospective assessment of disease activity
and of the effect of treatment in cats with IBD or FRE.
Results: The combination of gastrointestinal signs, endoscopic abnormalities, serum total protein, serum alanine
transaminase/alkaline phosphatase activity, and serum phosphorous concentration had the best correlation with histopatho-
logic inﬂammation and comprise the feline chronic enteropathy activity index (FCEAI). Positive treatment responses in cats
with CE were accompanied by signiﬁcant (Po .05) reductions in FCEAI scores after treatment.
Conclusions and Clinical Importance: The FCEAI is a simple numerical measure of inﬂammatory activity in cats with CE.
The scoring index can be reliably used in the initial assessment of disease severity for both IBD and FRE and as a measure of
clinical response to treatment for these disorders.
Key words: Clinical scoring; FCEAI; Feline chronic enteropathy activity index; Food-responsive enteropathy; Inﬂamma-
tory bowel disease.
The causes of chronic enteropathy (CE) in cats are di-verse but principally include idiopathic inﬂammatory
bowel disease (IBD) and food-responsive enteropathy
(FRE).1–7 Both of these disorders are characterized by
persistent or recurrent signs of gastrointestinal disease,
different pathogenetic mechanisms, and each is diagnosed
retrospectively by response to speciﬁc treatment.8 Clinical
signs in affected cats are highly variable and severity of
disease can differ greatly among cats, depending on the
type of enteropathy, localization, and extent of affected re-
gions of the gastrointestinal tract.1–3 Deﬁning disease
activity in cats with CE is of practical relevance to clini-
cians because it aids determination of initial disease burden
and serves to guide assessment of various therapies on in-
ﬂammatory activity. A suitable and quantiﬁable index, like
those utilized in humans9–12 and dogs with IBD,13,14 has
not been designed previously for use in cats.
The objective of the present study was to develop a
numerical index of the disease activity present in cats
with CE. We believed that such a clinical index should
contain the following requirements: (1) it should have
broad application to the most common forms of feline
CE, including IBD and FRE; (2) it should incorporate
gastrointestinal signs considered by clinicians to be im-
portant indicators of disease activity; (3) it should utilize
observations readily available at the time of a cat visit;
(4) it should contain objective parameters that are rou-
tinely measured during diagnostic evaluation; (5) it
should be simple to compute; and (6) it should reﬂect
visit-to-visit changes in disease status because of thera-
peutic interventions.9,13
The development of the feline chronic enteropathy ac-
tivity index (FCEAI) described herein is based on the
need for a useful clinical and research tool for assessment
of inﬂammatory activity in cats with CE. Moreover, the
evaluation of the FCEAI in a prospective pilot study
demonstrated the potential utility of this scoring index in
deﬁning disease activity at diagnosis and in response to
medical therapy.
Materials and Methods
Retrospective Study Criteria for Case Selection
Medical records of the Iowa State University, Veterinary Teach-
ing Hospital (ISU-VTH) were searched to identify all cats with a
diagnosis of idiopathic IBD between July 1993 and July 2003. The
resultant medical records were reviewed by one of the authors
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(J.C.). Cats were included in the study if they satisﬁed the clinical
criteria for idiopathic IBD including: persistent (43 weeks) gastro-
intestinal signs; failed responses to dietary (commercial intact
protein or hydrolysate elimination diets) or symptomatic (paracitic-
ides, antibiotics, gastrointestinal protectants) therapies alone;
thorough diagnostic evaluation with exclusion of other causes for
gastroenteritis; and histologic diagnosis of intestinal inﬂamma-
tion.1,15 All cats had been fed an elimination diet for a minimum of
14 days to rule out adverse food reactions. Additionally, metron-
idazole or amoxicillin with clavulanic acid had been administered to
most cats for 2–3 weeks if they failed to respond to dietary interven-
tion alone.
The minimum diagnostic evaluation performed on each cat in-
cluded a CBC, serum biochemistry proﬁle, urinalysis, feline trypsin-
like immunoreactivity (fTLI), direct (wet mount) and indirect (zinc
sulfate ﬂotation) examination of feces for nematode and protozoan
parasites, survey abdominal radiographs, and histopathologic re-
view of mucosal biopsy specimens (performed by different service
pathologists) obtained via gastroduodenoscopy, colonoscopy, or
both. The performance of a particular endoscopic procedure was
dictated by the history and predominant clinical signs exhibited by
each cat. Endoscopic examination was performed after therapeutic
trials. Thus, only cats fulﬁlling all 4 clinical criteria for IBD were
eligible for inclusion in the retrospective study. Exclusion criteria
included those cats that had responded positively to either dietary or
antimicrobial interventions or that had evidence of other underlying
disorders (based on results of diagnostic testing) causing chronic
gastroenteritis.
Data Collection
Signalment, salient history (including dietary and antibiotic ad-
ministration trials), clinical signs, clinicopathologic ﬁndings,
endoscopic observations, diagnostic imaging results, cytologic, and
histopathologic data were recorded. The selection of these variables
was based on analysis of previous evidence-based reports of IBD in
cats.1–4 A minimum of 5 biopsy specimens from the stomach, duo-
denum, and colon or some combination of these organs were
reexamined histologically and graded by a single pathologist
(M.A.). Intestinal inﬂammation was deﬁned using recently de-
scribed World Small Animal Veterinary Association
histopathologic guidelines.15,16 Histopathological severity (mild to
severe IBD) was based on alterations in mucosal height, villous
morphology, epithelial erosions or ulcers, edema/ﬁbrosis, inﬂam-
matory cell inﬁltration, and intraepithelial lymphocytes. Cats with
normal histology, intestinal neoplasia, infectious diseases, or other
potential causes for gastroenteritis were excluded. The number of
gastrointestinal signs (vomiting, diarrhea, weight loss, anorexia, and
lethargy) present in each cat was recorded. Endoscopic lesions of
mucosal friability, granularity, erosions or all the three were also
noted to be present or absent in IBD cats. Reference values were
total white blood cell (WBC): 5.5–19.5  103/mL; PCV: 30–45%;
total protein: 6.1–8.0 g/dL; albumin: 2.1–3.5 g/dL; alanine transa-
minase (ALT): 20–125 IU/L; serum alkaline phosphatase (ALP): 0–
60 IU/L; and phosphorous 4.0–7.6mg/dL.
Pilot Study
A single center (ISU-VTH) prospective study was performed
(2004–2006) and comprised a total of 23 cats referred for diagnostic
evaluation of CE. A standard diagnostic examination was perfor-
med in each cat and included a CBC, serum biochemistry proﬁle,
urinalysis, fecal examinations for parasites, survey abdominal ra-
diographs, abdominal ultrasound, and tests for gastrointestinal
function including measurement of serum fTLI concentration, se-
rum feline pancreatic lipase immunoreactivity (fPLI) concentration,
and serum folate and cobalamin concentration. Each cat was
assigned a baseline (pretreatment) FCEAI score as described in re-
sults. All cats were treated initially with an intact protein
elimination dieta,b,c fed exclusively for at least 14 days. Cats that re-
sponded to the elimination diet, as evidenced by improved or
completely resolved clinical signs alone, were assigned a diagnosis
of FRE and maintained on the elimination diet indeﬁnitely.
Those cats that failed to respond to dietary intervention underwent
gastrointestinal endoscopy and mucosal biopsy specimens. Histo-
pathologic evaluation was performed by the same pathologist
(M.A.) by identical grading criteria. Cats diagnosed with idiopathic
IBD were maintained on the elimination diet and were administered
prednisolone (2mg/kg PO per day) for 21 days followed by a taper-
ing dosage over 4–6 weeks. Both FRE and IBD cats were
reevaluated and assigned a FCEAI score at the end of the 21-day
induction treatment period.
Ethical Considerations
The retrospective and pilot studies were approved by the ISU In-
stitutional Animal Care and Use Committee. All clients gave
written or verbal informed consent for enrollment of their pet into
the prospective clinical trial.
Data Analysis and Statistics
Multivariate logistic regression was used to determine which of
the 13 independent variables identiﬁed from the data of the retro-
spective study best predicted the ordinal histopathological severity
of IBD (dependent variable). The potential association between
gastrointestinal signs and intestinal inﬂammation was examined us-
ing the variable appetite combined with alterations in attitude/
activity, vomiting, diarrhea, or weight loss. The relationship be-
tween each of the independent variables and a histologic diagnosis
of IBD was then determined and expressed as a P-value.
For the pilot study, the pretreatment scores between IBD and
FRE were compared by Wilcoxon’s rank-sum tests. A paired sam-
ple Wilcoxon’s signed-rank test was applied to test the score
difference before and after treatment for each of the IBD group
and FRE group. Statistical analyses were performed with SAS soft-
ware. For all analyses, a P-value ofo.05 was considered signiﬁcant.
Results
Retrospective Study
Sixty-six cats were initially diagnosed with idiopathic
IBD. Reexamination of biopsy specimens reduced the
number of cats with IBD to 60. These reasons included 2
cats diagnosed with well-differentiated alimentary lym-
phoma, 1 cat diagnosed with epitheliotropic lymphoma,
1 cat diagnosed with a mast cell tumor, and 2 cats that
had no histopathologic evidence of intestinal inﬂamma-
tion. An additional cat, suspicious for FIP based on
laboratory results, was also excluded from the study.
The mean age of the 59 remaining cats with IBD was 7.7
years with a range of 1.3–15 years. Thirty-ﬁve (55%) of
the diseased cats were spayed females and 24 (45%)
were neutered males. A total of 9 breeds were repre-
sented with the most common being domestic short hair
(49%) followed by domestic long hair (29%), Siamese
(7%), and Persian (5%). All other breeds represented
o10% of the total population. The independent vari-
ables studied in all 59 cats with IBD are shown in Table 1.
The means  standard deviations for variables with ap-
proximately bell-shaped distributions were body weight
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(4.01 1.4kg); PCV (371 6%); total protein (7.01 1.2g/dL);
albumin (2.7 1 0.8 g/dL); and phosphorous (3.7 1
1.3mg/dL), respectively. The medians and ranges for
variables with skewed distributions were total WBC
(10.4  103/mL, 5.2–35.4  103/mL); ALT (61, 10–
737 IU/L); and ALP (27, 9–132 IU/L). Fifty of 59 cats
(85%) had mucosal lesions of increased friability, granu-
larity, erosions, or all three on gastrointestinal end-
oscopic examination. Histologically, all cats showed
variable inﬁltration of lymphocytes, plasma cells, and
eosinophils into the lamina propria, which was accom-
panied by mucosal inﬂammation. The ﬁnal histo-
pathologic diagnoses were mild IBD (n 5 25), moderate
IBD (n 5 24), and severe IBD (n 5 10). Other abnor-
malities in cats with IBD included hypocobalaminemia
(mean serum cobalamin concentrationo100 ng/L) in 3/8
cats, which had serum cobalamin concentrations evalu-
ated and radiographic evidence of nonspeciﬁc enteritis
(eg, ﬂuid distended small intestinal bowel loops) in 15/59
(25%) cats.
Each independent variable in Table 1 was coded in
such a way that the anticipated value in a normal cat was
0, and that a value40 was expected to measure progres-
sively greater activity of CE. As a result of the pilot
analysis performed on this large data set, the number of
independent variables was reduced from 13 to 9 (Table 2).
These other variables were dropped because they were
shown to be poorly associated with histopathologic se-
verity of intestinal inﬂammation and the clinician’s
subjective impression of disease activity. The remaining
5 independent variables of gastrointestinal signs, endo-
scopic lesions, serum total protein, serum ALT/ALP,
and serum phosphorus concentrations that best pre-
dicted the dependent variable and which met the
requirements set forth for the index were chosen as com-
ponents of the FCEAI (Table 2). The variable ALT was
initially dropped from the index but later reinstated and
combined with ALP as a single parameter because of the
importance attributed to it by previous studies, as well as
intuitively by the participating clinicians.1–4 An example
of how to calculate the FCEAI in a cat with IBD is
shown in Table 3.
Pilot Study
In order to gain an impression of the clinical utility of
the FCEAI in cats with CE, the index was prospectively
evaluated in 23 cats having chronic gastrointestinal
signs. The baseline characteristics of the 2 groups of
cats were broadly similar (Table 4). Both forms of CE
had numerous laboratory abnormalities present at the
time of diagnosis including hyperproteinemia, hypoco-
balaminemia, hypophosphatemia, and increased serum
activity of liver derived enzymes. Additionally, some cats
in both groups (3 cats with IBD and 3 cats with FRE)
showed increase in serum fPLI (mean serum fPLI 5
8.8 mg/L and 7.6 mg/L in cats with IBD and FRE, respec-
tively). Results of diagnostic imaging showed nonspeciﬁc
ﬁndings of enteritis (ie, ﬂuid-distended small bowel
loops, thickened intestinal walls, mesenteric lymph-
adenopathy) and changes suggestive of pancreatitis (ie,
presence of a cranial abdominal mass, pancreatic hypo-
echogenicity, peripancreatic hyperechoic fat17) in 7/23
(30%) and 4/23 (17%) of diseased cats, respectively.
Ultrasonographic changes to the morphology of the small
intestines were usually diffuse but were most evident in the
duodenum and proximal jejunum. Focal wall (duodenal)
thickening observed in 3 cats with IBD was consistent with
a diagnosis of mixed mucosal inﬂammation, evidenced by
Table 1. Independent variables used in development of
activity index.
Variable Unit/Code
Attitude/activity 05 normal; 15 slight decrease; 25moderate
decrease; 35 severe decrease
Appetite 05 normal; 15 slight decrease; 25moderate
decrease; 35 severe decrease
Vomiting 05 none; 15mild (1 time/wk); 25moderate
(2–3 times/wk); 35 severe (43 times/wk)
Diarrhea 05 well-formed feces; 15 slightly soft feces,
fecal blood, mucus, or slightly increased fre-
quency (2–3 times/d); 25 very soft feces or
moderately increased frequency (4–5 times/d);
35 watery diarrhea or severely increased fre-
quency (45 times/d)
Weight loss 05 none; 15mild (o5% loss); 25moderate
(5–10% loss); 3 5 severe (410% loss)
Total WBC Count103/mL
PCV %
Total protein g/dL
Albumin g/dL
ALT IU/L
ALP IU/L
Phosphorous mg/dL
Endoscopic lesions Granularity, friability, ulcer/crosions
ALT, alanine aminotransferase; ALP, alkaline phosphatase;
WBC, white blood cell.
Table 2. Derivation of the FCEAI.
Variable Assessment P-Value Inclusion
GIT signs No or yes .088 Yes
Attitude/activity
Appetite Scored
Vomiting 0–3a
Diarrhea
Weight loss
Endoscopic lesions 05 no; 15 yes .035 Yes
Total WBC 05 normal; 1 5 increased .133 No
PCV 05 normal; 1 5 decreased .176 No
Total protein 05 normal; 1 5 increased .054 Yes
Albumin 05 normal; 1 5 decreased .126 No
ALT 05 normal; 1 5 increased .107 Yesb
ALP 05 normal; 1 5 increased .044 Yes
Phosphorous 05 normal; 1 5 decreased .085 Yes
ALT, alanine aminotransferase; ALP, alkaline phosphatase;
FCEAI, feline chronic enteropathy activity index; WBC, white
blood cell.
aFor codes see Table 1.
bCombined with ALP as a single variable.
3
77775
1029Gastrointestinal Disease Activity Index for Cats
lymphocytic, plasmacytic, and eosinophilic inﬁltrates
based on results obtained from ﬁne-needle aspiration
cytology. Endoscopic lesions of increased granularity,
friability, erosions, or all three to the intestines were seen
in 16/17 (94%) of the cats with IBD. A greater number
of endoscopic abnormalities were generally associated
with increasing severity of clinical disease. Care was
taken to obtain multiple mucosal specimens from both
the duodenum and jejunum in all cats. Histopathologic
lesions in all cats with IBD were characterized by vari-
able degrees of lymphocytic-plasmacytic (LP) mucosal
inﬂammation.
The mean FCEAI score of the FRE group was 6.7 be-
fore initiating the elimination dietary trial with a range
from 5 to 9, and decreased to 0 after 21 days of treatment
(P 5 .03; Fig 1). All cats responded to dietary interven-
tion alone with dramatic resolution of signs within the
ﬁrst 10 days. In cats with IBD, the mean FCEAI score
was 8.2 before endoscopic examination (range 4–13) and
decreased to 0.4 (range 0–2) after treatment with the
elimination diet and oral prednisolone (Po .001; Fig 1).
No signiﬁcant difference of pretreatment FCEAI scores
was observed between cats with IBD and FRE (P5 .18).
All 17 cats with IBD (100%) achieved full clinical remis-
sion, deﬁned as a 75% or greater reduction in
posttreatment FCEAI score compared with its corre-
sponding pretreatment value after 3 weeks of induction
medical therapy. Interobserver variation of FCEAI
scores performed on the same cat by the 2 clinicians
(A.J., J.C.) was very good for both initial and repeat vis-
its (complete agreement between clinicians in 16 and 20
cats), regardless of the form of CE evaluated. There was
occasional disagreement of 1 point of cumulative total in
scoring among clinicians in a subset of cats with IBD on
the initial (pretreatment) visit. However, there was com-
plete agreement among clinicians in the posttreatment
FCEAI scores for 9/10 cats with IBD that were evaluated
independently by both clinicians during the same visit
(data not shown).
Table 3. Example of calculation of the FCEAI for a
given patient.
Gastrointestinal signs
Endoscopic lesions
Total protein
ALT/ALP
Phosphorous
mod, moderate; sev, severe.
Table 4. Distribution of some clinicopathologic vari-
ables in feline CE.
Variable FIBD (n5 17) FRE (n5 6)
Male sex, n (%) 7 (41) 3 (50)
Mean age (years) 10.4 7.7
Disease duration (months) 4.8 6.0
Gastrointestinal signs, n (%)
Attitude/activity 10 (59) 4 (66)
Appetite 12 (71) 5 (80)
Vomiting 11 (65) 4 (66)
Diarrhea 9 (53) 3 (50)
Weight loss 13 (76) 4 (66)
Laboratory abnormalities, n (%)
Hyperproteinemia 3 (18) 2 (33)
" ALP/ALT 4 (23) 1 (17)
Hypocobalaminemia 3 (18) 1 (17)
" fPLI 3 (18) 3 (50)
Hypophosphatemia 8 (47) 2 (33)
FIBD, feline inﬂammatory bowel disease; FRE, food responsive
enteropathy; ALP, alkaline phosphatase; ALT, alanine aminotr-
ansferase; fPLI, feline pancreatic lipase immunoreactivity; CE,
chronic enteropathy.
Fig 1. Effect of medical therapy on clinical disease activity in food-
responsive and cats with IBD based on FCEAI scores. Box plots
show the mean, range, 25 and 75% quartiles for FCEAI scores. P
o .05 compared with pretreatment value. IBD, inﬂammatory bowel
disease; FRE, food-responsive enteropathy; Tx, treatment; FCEAI,
feline chronic enteropathy activity index.
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Discussion
The present study utilized 2 separate but complemen-
tary approaches to develop and assess the FCEAI. First,
in a retrospective analysis of 59 cats diagnosed with idio-
pathic IBD, clinicopathologic and endoscopic variables
were evaluated for their potential association with histo-
pathologic lesions of intestinal inﬂammation. Five
independent variables correlated best to histopathologic
inﬂammation and were selected for the ﬁnal calculation
of the FCEAI.We thought it necessary to have a uniform
set of parameters that could be temporally assessed and
recorded by clinicians at different centers. This would
allow data collected at each center to be comparable with
those collected at other centers, and for data to be com-
pared when collected at different times. Furthermore, a
numerical index was needed whereby the magnitude of
the numerical value would be proportional to the degree
of disease activity. This index could then serve as the
principal measure of response to a therapeutic trial and
could also be used to tailor medical therapy for an indi-
vidual cat’s need.
Secondly, validation of the potential utility of the
FCEAI was assessed in a prospective clinical trial of 23
cats presented with histories of chronic gastrointestinal
disease. Seventeen cats diagnosed with IBD were fed an
elimination diet and prescribed prednisolone (2mg/kg
PO q24h) whereas FRE cats were fed an elimination diet
alone. The FCEAI score was determined before and dur-
ing therapeutic intervention (at treatment day 21).
Collectively, the data of the present study indicate that
the FCEAI is a useful method for assessing clinical dis-
ease activity in cats with IBD or FRE at diagnosis.
Furthermore, positive treatment responses were accom-
panied by changes in the FCEAI, suggesting that this
clinical scoring system is suitable for monitoring the
effect of induction therapy in cats with CE.
The association among clinical signs, laboratory ﬁnd-
ings, and histopathology of FCE has been reported in
relatively few case-based studies. The occurrence of gas-
trointestinal signs, hyperproteinemia, increased serum
ALT activity, endoscopic abnormalities, and severity of
histopathologic lesions is reported for 26 cats with IBD.1
Cats diagnosed with LP) gastroenteritis2 or LP colitis3
had anorexia, vomiting, watery diarrhea, and large bowel
diarrhea that were accompanied by hypoproteinemia,
high serum ALT and ALP activity, endoscopic changes
to the intestinal mucosa, and histopathologic inﬂamma-
tion that varied among different anatomic sites in the
same cat. Similarly, 60 cats diagnosed with LP enteroco-
litis had signs of gastrointestinal disease, increased serum
activity of ALT and ALP enzymes, hyperproteinemia,
and intestinal inﬂammation of varying severity.4 Still
others have shown a positive correlation among the num-
ber of gastrointestinal signs, mucosal proinﬂammatory
cytokine expression, duodenal histopathology, and mu-
cosally associated bacteria in cats with IBD.18
Additionally, cats with FRE can have concurrent signs
of gastrointestinal disease with dermatologic disease;
however, only mild histopathologic changes and infre-
quent biochemical changes were noted in food-sensitive
cats.5,19 The emergent themes of these earlier studies, in-
cluding the presence of salient gastrointestinal signs,
biochemical alterations, endoscopic lesions, and LP mu-
cosal inﬂammation in cats with CE, formed the
framework for determining whether these and other in-
dependent variables correlated most closely with
intestinal inﬂammation in design of the FCEAI.
Hypocobalaminemia and increased serum fPLI concen-
trations occur in some IBD and FRE cats. Low serum
cobalamin concentration has been described previously in
cats with enteric, hepatic, pancreatic disease, or all three,
and has been associated with refractoriness to treatment in
cats with CE.20,21 Relatively few cats with IBD in the
retrospective study had cobalamin concentrations
assessed that precluded its evaluation as an indepen-
dent variable in the FCEAI. The reasons for exclusion
of this diagnostic test in some cats included the absence
of a commercially available, validated assay during
the early portion of the retrospective study time frame,
case-dependent treatment decisions such as empirical
cobalamin supplementation made by different clinicians,
and client cost constraints. However, hypocobalaminemia
was a more consistent observation in both cats with IBD
and FRE of the pilot study. Six of 7 (5 with IBD and 1 with
FRE) cats with hypocobalaminemia in this study were suc-
cessfully treated with weekly cobalamin injections which
corrected the cobalamin concentrations into the reference
range within 6 weeks after initiating vitamin therapy. One
other cat with IBD required intermittent weekly cobalamin
injections, along with maintenance glucocorticoid and
elimination dietary therapies, beyond this timeframe to
maintain clinical remission.
It is also possible that some cats with IBD also had
pancreatic inﬂammation, evidenced by increased serum
fPLI concentrations, which would have contributed to
onset and progression of gastrointestinal signs. Support-
ing this contention were the abnormalities in the
pancreas and intestines detected on diagnostic imaging
in some cats. While cats with IBD might have increased
serum fPLI concentrations, this association does not ap-
pear to inﬂuence clinical outcome based on a recent
report.d Previous investigations have suggested a poten-
tial causal association among small intestinal
inﬂammation, pancreatitis, and hepatic disease such as
triaditis in cats with histories of CE.20,22–24 However,
these earlier data were derived from retrospective studies,
have focused on distinct subsets of cats, have utilized
different indices for diagnosis of organ-speciﬁc disease,
and have not conﬁrmed a distinct temporal relationship
among pancreatic, hepatic, and intestinal inﬂamma-
tion—namely that they occurred simultaneously.
Furthermore, alterations in tissue morphology do not al-
ways indicate disturbances in organ fuction or the
presence of clinically signiﬁcant inﬂammation.25,26 Addi-
tional studies are warranted to determine whether
cobalamin and fPLI are useful variables in the long-term,
overall clinical assessment of cats with CE.
Hypophosphatemia was a relatively common electro-
lyte abnormality observed in cats with CE at initial
presentation. Low serum phosphorus concentrations
might be caused by maldistribution (translocation of
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phosphate from extracellular to intracellular ﬂuid),
increased loss (reduced renal absorption of phosphate),
or decreased intake (decreased intestinal absorption
of phosphate).27 The causes for hypophosphatemia in
some cats of the present study remain unknown, but
might be attributable to malnourishment, malabsorptive
disorders, and chronic vomiting or some combination of
these etiologies.28 Serum concentrations of phosphorous
normalized in most hypophosphatemic cats (data not
shown) after successful treatment for their underlying
gastrointestinal disease.
Endoscopic lesions to the small intestinal mucosa were
the FCEAI variable most signiﬁcantly associated with
histologic abnormalities. Consistent with earlier reports,
endoscopic observations of mucosal friability, granular-
ity, and erosions or some combination of these lesions
predominated in most cats with IBD.1,2 Surprisingly, the
presence of endoscopic abnormalities did not appear to
inﬂuence short-term response to treatment, as all cats
with IBD in the pilot study had full clinical remission by
treatment day 21. Whether endoscopic severity in cats
with IBD is associated with long-term negative outcome,
as it has been shown in dogs with IBD, will require ad-
ditional investigation.14
The proposed index incorporates assessment of the dy-
namic changes in individual variables that best reﬂect the
disease course in cats with CE. This is possible
because the FCEAI is composed of a set of clinical and
laboratory parameters that permit repeated measures,
the exception being endoscopic abnormalities which may
not be evaluated in cats with FRE or reevaluated in most
cats with IBD that respond favorably to medical therapy.
When repeat endoscopy is not possible, omission of this
variable is required, which will automatically decrease
the posttreatment FCEAI score, assuming that end-
oscopic lesions were present on the initial examination,
by 1 point. The use of only 5 variables in calculation of
posttreatment disease severity should be taken into con-
sideration when evaluating the efﬁcacy of medical
therapy in these instances. Another advantage and im-
portant feature of this index is that it contains a number
of objective variables including serum total protein,
ALT and ALP activities, and phosphorus concentrations
which can be quantiﬁed. To systematically assess the
usefulness of the FCEAI in cats with CE, we prospec-
tively compared baseline (pretreatment values
determined at diagnosis) and posttreatment FCEAIs in
17 cats with IBD and 6 cats with FRE. Both disease
groups showed signiﬁcant reduction in their mean
FCEAI scores by 21 days posttreatment which agreed
with the clinician’s overall assessment of clinical illness.
Moreover, the decline in FCEAI scores observed post-
treatment in these cats was generally associated with
numerical reductions in both clinical and laboratory
variables alike, suggesting that the index is suitably
weighted by both sets of parameters.
The present study has some potential limitations. We
cannot conclusively exclude infection with Tritrichomonas
foetus as contributing to large bowel diarrhea in some cats.
Speciﬁc tests such as selective protozoal culture or poly-
merase chain reaction with species-speciﬁc primers for
diagnosis of T. foetus infection were not performed in the
retrospective study as this protozoan was not a recognized
pathogen in cats at this time.29,30 However, we consider it
unlikely that infection with T. foetus was present because
most cats were middle-aged, relatively few cats presented
with signs of large bowel disease alone, signiﬁcant risk fac-
tors (ie, multi-cat household or kennel facility) for disease
were rarely evident, and at least 1 direct fecal examination
for detection of parasitic organisms was performed in all
cats.
It is a possibility that some cats were incorrectly diag-
nosed with IBD versus well-differentiated alimentary
lymphoma, especially in the retrospective portion of this
study.31,32 To minimize this potential, we utilized a single
experienced veterinary pathologist (M.A.) with expertise
in gastrointestinal histopathology to review all endo-
scopic specimens. Histopathologic examination of duo-
denal tissues from 3/66 cats in the original IBD
retrospective study population resulted in the reclassiﬁ-
cation of these cats into a ﬁnal disease category of
intestinal lymphoma. It is our approach to ﬁrst perform
routine morphologic and immunophenotypic analysis of
histologic tissues followed by assessment of clonality
when lymphoma is a differential diagnosis. Molecular
clonality determination of feline lymphoma was not per-
formed in any cats of this study to conclusively exclude
alimentary lymphoma.33,34 As discussed by others, pro-
curement of full-thickness biopsy specimen from all
segments of the intestine with the collection of extrain-
testinal samples, especially mesenteric lymph nodes, may
be helpful in diagnosing feline intestinal lymphoma.35,36
Moreover, older cats with ultrasonographic evidence of
muscularis propria thickening are more likely to have
lymphoma versus IBD.37 Endoscopic biopsy specimen of
the upper small intestine (duodenum, jejunum in some
instances) was performed in all cats of the present study
and may have missed more distal sites (eg, ileal mucosa)
of neoplastic cellular inﬁltration. Therefore, ileal biopsy
specimens should be obtained in cats to increase
diagnostic yield whenever gastroduodenoscopy or colon-
oscopy is performed, especially because smaller diameter
feline endoscopes now make endoscopic biopsy
specimens of the ileum easier to perform.15,35,36 This rec-
ommendation is supported by our observation that 4 cats
in the retrospective or pilot study had concurrent ileos-
copy performed which conﬁrmed IBD (n 5 2) or
lymphoma (n5 2), respectively.
Footnotes
a IVD feline Neutral formula, Royal Canin USA Inc, St Charles,
MO
b IVD feline Sensitivity formula, Royal Canin USA Inc
c IVD feline Green Pea and Duck formula, Royal Canin USA Inc
d Bailey S, Benigni L, Eastwood J, et al. Clinical signiﬁcance of in-
creased serum feline pancreatic lipase immunoreactivity
concentrations in cats with inﬂammatory bowel disease. J Vet In-
tern Med 2009;23:734–735 (abstract)
1032 Jergens et al
Acknowledgment
The authors gratefully acknowledge Waltham for pro-
viding research funding for performance of these clinical
studies.
References
1. Jergens AE, Moore FM, Haynes JS, et al. Idiopathic inﬂam-
matory bowel disease in dogs and cats: 84 cases (1987–1990). J Am
Vet Med Assoc 1992;201:1603–1608.
2. Dennis JS, Kruger JM, Mullaney TP. Lymphocytic/plas-
macytic gastroenteritis in cats: 14 cases (1985–1990). J Am Vet Med
Assoc 1992;200:1712–1718.
3. Dennis JS, Kruger JM, Mullaney TP. Lymphocytic/plas-
macytic colitis in cats: 14 cases (1985–1990). J Am Vet Med Assoc
1993;202:313–318.
4. Hart JR, Shaker E, Patnaik AK, et al. Lymphocytic-plas-
macytic enterocolitis in cats: 60 cases (1988–1990). J Am Anim
Hosp Assoc 1994;30:505–514.
5. GuilfordWG, Jones BR,Markwell PJ, et al. Food sensitivity
in cats with chronic idiopathic gastrointestinal problems. J Vet In-
tern Med 2001;15:7–13.
6. Nelson RW, Dimperio ME, Long GG. Lymphocytic-
plasmacytic colitis in the cat. J Am Vet Med Assoc 1984;184:
1133–1135.
7. Wasmer ML, Willard MD, Helman RG, et al. Food intoler-
ance mimicking alimentary lymphosarcoma. J Am Anim Hosp
Assoc 1995;31:463–466.
8. Hall EJ, German AJ. Diseases of the small intestine. In: Et-
tinger SJ, Feldman EC., eds. Textbook of Veterinary Internal
Medicine, 6th ed. Philadelphia, PA: Saunders; 2004:1332–1378.
9. BestWR, Bectel JM, Singleton JW, et al. Development of the
Crohn’s disease activity index. Gastroenterology 1976;70:439–444.
10. Harvey RF, Bradshaw JM. A simple index of Crohn’s dis-
ease activity. Lancet 1980;1:514.
11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final
report on a therapeutic trial. Br Med J 1955;2:1041–1044.
12. Van Hees PAM, Van Elteren Ph, Van Lier HJJ, et al. An in-
dex of inﬂammatory activity in patients with Crohn’s disease. Gut
1980;21:279–286.
13. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index
for disease activity in canine inﬂammatory bowel disease. J Vet In-
tern Med 2003;17:291–297.
14. Allenspach K, Wieland B, Grone A, et al. Chronic entero-
pathies in dogs: Evaluation of risk factors for negative outcome.
J Vet Intern Med 2007;21:700–708.
15. Washabau RJ, Day MJ, Willard MD, et al. 2009 ACVIM
Consensus Statement: Endoscopic, biopsy, and histopathologic
guidelines for the evaluation of gastrointestinal inﬂammation in
companion animals. J Vet Intern Med 2010;24:10–26.
16. Day MJ, Bilzer T, Mansell J, et al. International standards
for the histopathological diagnosis of gastrointestinal inﬂammation
in the dog and cat: A report from the World Small Animal Veter-
inary Association Gastrointestinal Standardization Group. J Comp
Pathol 2008;1(Suppl 1):S1–S43.
17. Xenoulis PG, Steiner JM. Current concepts in feline pan-
creatitis. Top Companion Anim Med 2008;23:185–192.
18. Janeczko S, Atwater D, Bogel E, et al. The relationship of
mucosal bacteria to duodenal histopathology, cytokine mRNA, and
clinical disease activity in cats with inﬂammatory bowel disease. Vet
Microbiol 2008;128:178–193.
19. Verlinden A, Hesta M, Millet S, et al. Food allergy in dogs
and cats: A review. Crit Rev Food Sci Nutr 2006;46:259–273.
20. Simpson KW, Fyfe J, Cornetta A, et al. Subnormal concen-
trations of serum cobalamin (vitamin B12) in cats with
gastrointestinal disease. J Vet Intern Med 2001;15:26–32.
21. Ruaux CG, Steiner JM, Williams DA. Early biochemical
and clinical responses to cobalamin supplementation in cats with
signs of gastrointestinal disease and severe hypocobalaminemia.
J Vet Intern Med 2005;19:155–160.
22. Weiss DJ, Gagne JM, Armstrong PJ. Relationship between
inﬂammatory hepatic disease and inﬂammatory bowel disease,
pancreatitis, and nephritis in cats. J Am Vet Med Assoc 1996;209:
1114–1116.
23. Hill RC, Van Winkle TJ. Acute necrotizing pancreatitis in
acute suppurative pancreatitis in the cat: A retrospective study of 40
cases (1976–1989). J Vet Intern Med 1993;7:25–33.
24. Akol KG, Washabau RJ, Saunders HM, et al. Acute pan-
creatitis in cats with hepatic lipidosis. J Vet Intern Med 2001;15:
327–228.
25. Weiss DJ, Gagne JM, Armstrong PJ. Characterization of
portal lymphocytic inﬁltrates in feline liver. Vet Clin Path 1995;
24:91–95.
26. deCock HEV, FormanMA, Farver TB, et al. Prevalence and
histopathologic characteristics of pancreatitis in cats. Vet Pathol
2007;44:39–49.
27. DiBartola SP, WillardMD. Disorders of phosphorus: Hypo-
phosphatemia and hyperphosphatemia. In: Dibartola SP., ed.
Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Prac-
tice, 3rd ed. Philadelphia, PA: Saunders; 2006:195–209.
28. Chew DJ, Meuten DJ. Disorders of calcium and phosphorus
metabolism. Vet Clin North Am Small Anim Pract 1982;12:411–438.
29. Gookin JL, Stauffer SH, Levy MG. Identiﬁcation of Penta-
trichomonas hominis in feline fecal samples by polymerase chain
reaction assay. Vet Parasitol 2007;145:11–15.
30. Bisset SA, Gowan RA, O’ Brien CR, et al. Feline diarrhea
associated with Tritrichomonas cf. foetus and Giardia co-infection
in an Australian cattery. Aust Vet J 2008;86:440–443.
31. Richter KP. Feline gastrointestinal lymphoma. Vet Clin
North Am Small Anim Pract 2003;33:1083–1098.
32. Gabor LJ, Canﬁeld PJ, Malik R. Immunophenotypic and
histological characterization of 109 cases of feline lymphosarcoma.
Aust Vet J 1999;77:436–441.
33. Werner JA, Woo JC, Graham PS, et al. Characterization of
feline immunoglobulin heavy chain variable region genes for the
molecular diagnosis of B-cell neoplasia. Vet Pathol 2005;42:
596–607.
34. Moore PF, Woo JC, Vernau W, et al. Characterization of
feline T receptor gamma (TCRG) variable region genes for the mo-
lecular diagnosis of feline intestinal T cell lymphoma. Vet Immunol
Immunopathol 2005;106:167–178.
35. Evans SE, Bonczynski JJ, Broussard JD, et al. Comparison
of endoscopic and full-thickness biopsy specimens for diagnosis of
inﬂammatory bowel disease and alimentary tract lymphoma in cats.
J Am Vet Med Assoc 2006;229:1447–1450.
36. Kleinschmidt S, Harder J, Nolte I, et al. Chronic inﬂamma-
tory disease of the gastrointestinal tract in cats: Diagnostic
advantages of full-thickness intestinal and extraintestinal biopsies.
J Feline Med Surg 2010;12:97–103.
37. Zwingenberger AL, Marks SL, Baker TW, et al. Ultrasono-
graphic evaluation of the muscularis propria in cats with diffuse
small intestinal lymphoma or inﬂammatory bowel disease. J Vet In-
tern Med 2010;24:289–292.
1033Gastrointestinal Disease Activity Index for Cats
